Skip to content
Learn More

Resources

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

December 28, 2020

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom …

Read More

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

December 1, 2020

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first Statement of Work (“SoW”) under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using …

Read More

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

November 24, 2020

– Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development Program – BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,844,392, entitled “Materials and Methods …

Read More

iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

November 3, 2020

– Brings >20 Years of Global Biotech Operations and Business Development Experience – BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Randy J. Maddux as its Chief Operating Officer (“COO”), effective December 1, 2020. Mr. Maddux has …

Read More

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

October 2, 2020

– Project Focused on Proteins used in the Production of Blood Cells – NEW YORK, Oct. 02, 2020 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it has entered into a Master Services Agreement (“MSA”) with Boston-based Safi Biosolutions, Inc. (“Safi”) …

Read More
Top